A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML

Bibliographic Details
Main Authors:	Daver, NG, Montesinos, P, Aribi, A, Martinelli, G, Altman, J, Roboz, G, Wang, ES, Burke, PW, Jeyakumar, D, Walter, RB, DeAngelo, DJ, Erba, HP, Advani, A, Gastaud, L, Thomas, X, Todisco, E, Pemmaraju, N, Mendez, L, de la Fuente, A, Gaidano, G, Curti, A, Boissel, N, Recher, C, Schliemann, C, Vyas, P, Sloss, CM, Wang, J, Malcolm, KA, Zweidler‐McKay, PA, Sweet, KL
Format:	Conference item
Language:	English
Published:	Wolters Kluwer Health, Inc. 2022

Similar Items